Literature DB >> 920780

Newer insights into the pathogenesis of liver cancer.

E Farber, D Solt, R Cameron, B Laishes, K Ogawa, A Medline.   

Abstract

A new hypothesis leading to a new model of liver carcinogenesis is described; it is based on the acquisition by carcinogen-altered hepatocytes during initiation of a new functional handle--resistance to the cytotoxicity of a carcinogen--and on the ability of such cells to proliferate in an environment that prevents proliferation of normal hepatocytes. The creation of such a differential environment now enables a quantitative analysis for initiation, the beginning synchronization of the putative premalignant hepatocytes for about 15 cell cycles, the study of the pattern of growth of such resistant cells to form nodules that have some resemblance to the organizational pattern of fetal liver, the analysis of the appearance of distinctive positive and negative markers for these cells, and the further investigation of the development of liver cancer from such cells. The remarkable similarity in overall pattern betweeen the development of cancer in the skin and in the liver with chemicals and the possible role of both somatic mutation and neodifferentiation in carcinogenesis are briefly discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 920780      PMCID: PMC2032235     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  10 in total

1.  Functional and structural alterations of liver ergastoplasmic membranes during DL-ethionine hepatocarcinogenesis.

Authors:  E Gravela; F Feo; R A Canuto; R Garcea; L Gabriel
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

Review 2.  Carcinogenesis--cellular evolution as a unifying thread: Presidential address.

Authors:  E Farber
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

3.  Responsiveness of hyperplastic lesions and hepatomas to partial hepatectomy.

Authors:  T Kitagawa
Journal:  Gan       Date:  1971-06

4.  The effect of L-asparaginase on mitotic activity during N-2-fluorenylacetamide hepatocarcinogenesis: subpopulations of nodular cells.

Authors:  F F Becker; K M Klein
Journal:  Cancer Res       Date:  1971-02       Impact factor: 12.701

5.  Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis.

Authors:  D B Solt; A Medline; E Farber
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

6.  Neoplastic transformation of fetal rat brain cells in culture after exposure to ethylnitrosourea in vivo.

Authors:  O D Laerum; M F Rajewsky
Journal:  J Natl Cancer Inst       Date:  1975-11       Impact factor: 13.506

7.  The resistance of putative premalignant liver cell populations, hyperplastic nodules, to the acute cytotoxic effects of some hepatocarcinogens.

Authors:  E Farber; S Parker; M Gruenstein
Journal:  Cancer Res       Date:  1976-11       Impact factor: 12.701

8.  Cytochrome P-450 in hyperplastic liver nodules during hepatocarcinogenesis with N-2-fluorenylacetamide in rats.

Authors:  K Okita; K Noda; Y Fukumoto; T Takemoto
Journal:  Gan       Date:  1976-12

9.  A relative deficiency of cytochrome P-450 and aryl hydrocarbon [benzo(a)pyrene] hydroxylase in hyperplastic nodules induced by 2-acetylaminofluorene in rat liver.

Authors:  R Cameron; G D Sweeney; K Jones; G Lee; E Farber
Journal:  Cancer Res       Date:  1976-11       Impact factor: 12.701

10.  Tissue regeneration and tumour development.

Authors:  J O LAWS
Journal:  Br J Cancer       Date:  1959-12       Impact factor: 7.640

  10 in total
  17 in total

1.  Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma.

Authors:  Heather Francois-Vaughan; Adeola O Adebayo; Kate E Brilliant; Nicola M A Parry; Philip A Gruppuso; Jennifer A Sanders
Journal:  Carcinogenesis       Date:  2016-02-10       Impact factor: 4.944

2.  Hepatitis B virus integration site in hepatocellular carcinoma at chromosome 17;18 translocation.

Authors:  O Hino; T B Shows; C E Rogler
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

3.  Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.

Authors:  Yan-Tong Guo; Xi-Sheng Leng; Tao Li; Jing-Ming Zhao; Xi-Hou Lin
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

4.  Neonatal streptozotocin treatment causes type 1 diabetes and subsequent hepatocellular carcinoma in DIAR mice fed a normal diet.

Authors:  Hayato Baba; Koichi Tsuneyama; Takeshi Nishida; Hideki Hatta; Takahiko Nakajima; Kazuhiro Nomoto; Shinichi Hayashi; Shigeharu Miwa; Yuko Nakanishi; Ryoji Hokao; Johji Imura
Journal:  Hepatol Int       Date:  2014-06-20       Impact factor: 6.047

5.  Metabolic Activation of PCBs to Carcinogens in Vivo - A Review.

Authors:  Gabriele Ludewig; Leane Lehmann; Harald Esch; Larry W Robertson
Journal:  Environ Toxicol Pharmacol       Date:  2008-03       Impact factor: 4.860

Review 6.  Enzymes of glutathione metabolism as biochemical markers during hepatocarcinogenesis.

Authors:  S Hendrich; H C Pitot
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 7.  Preleukemia. Cytogenetic clues in some confusing disorders.

Authors:  P C Nowell
Journal:  Am J Pathol       Date:  1977-11       Impact factor: 4.307

8.  Enzyme patterns in human hepatocellular carcinoma.

Authors:  M A Gerber; S N Thung
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

Review 9.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

Review 10.  Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma.

Authors:  Samuele De Minicis; Tatiana Kisseleva; Heather Francis; Gianluca Svegliati Baroni; Antonio Benedetti; David Brenner; Domenico Alvaro; Gianfranco Alpini; Marco Marzioni
Journal:  Dig Liver Dis       Date:  2012-11-22       Impact factor: 4.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.